362 related articles for article (PubMed ID: 30030798)
1. Clinical Interventions in HIV Cure Research.
Rasmussen TA; Søgaard OS
Adv Exp Med Biol; 2018; 1075():285-318. PubMed ID: 30030798
[TBL] [Abstract][Full Text] [Related]
2. Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?
Rasmussen TA; Lewin SR
Curr Opin HIV AIDS; 2016 Jul; 11(4):394-401. PubMed ID: 26974532
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
4. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
Front Immunol; 2020; 11():1112. PubMed ID: 32595636
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic approaches targeting HIV reservoirs].
Cheret A
Virologie (Montrouge); 2019 Aug; 23(4):250-259. PubMed ID: 31414662
[TBL] [Abstract][Full Text] [Related]
6. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
7. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 May; 91(9):. PubMed ID: 28202759
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF
J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022
[TBL] [Abstract][Full Text] [Related]
9. Between a shock and a hard place: challenges and developments in HIV latency reversal.
Zerbato JM; Purves HV; Lewin SR; Rasmussen TA
Curr Opin Virol; 2019 Oct; 38():1-9. PubMed ID: 31048093
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials aimed at HIV cure or remission: new pathways and lessons learned.
Schou MD; Søgaard OS; Rasmussen TA
Expert Rev Anti Infect Ther; 2023; 21(11):1227-1243. PubMed ID: 37856845
[TBL] [Abstract][Full Text] [Related]
11. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
[TBL] [Abstract][Full Text] [Related]
12. Reversal of Latency as Part of a Cure for HIV-1.
Rasmussen TA; Tolstrup M; Søgaard OS
Trends Microbiol; 2016 Feb; 24(2):90-97. PubMed ID: 26690612
[TBL] [Abstract][Full Text] [Related]
13. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
Bullen CK; Laird GM; Durand CM; Siliciano JD; Siliciano RF
Nat Med; 2014 Apr; 20(4):425-9. PubMed ID: 24658076
[TBL] [Abstract][Full Text] [Related]
14. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
15. Novel Latency Reversal Agents for HIV-1 Cure.
Spivak AM; Planelles V
Annu Rev Med; 2018 Jan; 69():421-436. PubMed ID: 29099677
[TBL] [Abstract][Full Text] [Related]
16. Cancer therapies in HIV cure research.
Rasmussen TA; Anderson JL; Wightman F; Lewin SR
Curr Opin HIV AIDS; 2017 Jan; 12(1):96-104. PubMed ID: 27607592
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments.
Kula A; Delacourt N; Bouchat S; Darcis G; Avettand-Fenoel V; Verdikt R; Corazza F; Necsoi C; Vanhulle C; Bendoumou M; Burny A; De Wit S; Rouzioux C; Rohr O; Van Lint C
J Acquir Immune Defic Syndr; 2019 Apr; 80(5):605-613. PubMed ID: 30768485
[TBL] [Abstract][Full Text] [Related]
18. Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.
Lee WS; Kristensen AB; Rasmussen TA; Tolstrup M; Østergaard L; Søgaard OS; Wines BD; Hogarth PM; Reynaldi A; Davenport MP; Emery S; Amin J; Cooper DA; Kan VL; Fox J; Gruell H; Parsons MS; Kent SJ
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539449
[TBL] [Abstract][Full Text] [Related]
19. What Will It Take to Cure HIV?
Ananworanich J
Top Antivir Med; 2015; 23(2):80-4. PubMed ID: 26200707
[TBL] [Abstract][Full Text] [Related]
20. Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
Kim Y; Anderson JL; Lewin SR
Cell Host Microbe; 2018 Jan; 23(1):14-26. PubMed ID: 29324227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]